[Pre- and intra-operative chemotherapy using FT-207 suppositories--with special reference to lung cancer].
This study was conducted to determine efficacy of FT-207 to prevent hematogenous peri-operative metastasis of lung cancer. A total of 16 patients consisting of 10 with squamous cell cancer, 6 with adenocarcinoma were evaluated in this study. The protocol of this study consisted of the pre-and peri-operative chemotherapy, giving 1000 mg of FT-207 suppository daily for 10 days. 5-FU plasma concentration in the systemic circulation during surgery was 0.01 mcg/ml. 5-FU tissue concentration of the normal lung was 0.07 mcg/g, and cancerous tissue (squamous cell ca 0.11 mcg/g, adenocarcinoma 0.12 mcg/g), and lymph nodes 0.15 mcg/g. It was found in this study that the pre-and peri-operative adjuvant chemotherapy with FT-207 was effective to prevent operation-induced hematogenous metastasis of lung cancer.
D000230:Adenocarcinoma / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000378:metabolism; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000378:metabolism; D006801:Humans; D007430:Intraoperative Care; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000601:surgery; D011300:Preoperative Care; D013488:Suppositories; D005641:Tegafur / Q000008:administration & dosage*
D000970:Antineoplastic Agents; D013488:Suppositories; D005641:Tegafur; D005472:Fluorouracil